Eli Lilly statement on Chinese media report

Eli Lilly statement on Chinese media report
 
We are deeply concerned about the allegations made against Lilly China published on August 21, 2013 in the 21st Century Business Herald.
 
First, there is no former Lilly senior manager in China named Wang Wei; as indicated in the article, it is a fictitious name. However, we were made aware of very similar allegations in 2012 by a former sales manager in the same region. At the time of the allegations, we did an exhaustive investigation to search for any evidence of kickbacks. The investigation was very thorough and included employee interviews, e-mail monitoring, and expense report audits.  Although we have not been able to verify these allegations, we take them seriously, and we are continuing our investigation. 
 
As part of our mission to improve global health, Lilly brings innovative medicines to patients, and also shares important scientific medical information with physicians and scientists for the benefits of their patients. We have processes designed to ensure we implement our programs in accordance with the highest ethical standards and in compliance with the law. Integrity is foremost among the values that have guided Lilly and its employees for more than 137 years.

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.